Bengaluru: India’s largest biotechnology company, Biocon Ltd, is planning to make a push into niche areas of the US generic drug market to tap existing resources better and make extra money while it awaits bigger rewards from its huge bet on biosimilars down the road.
Generic drugs are cheaper but exact replicas of branded chemical drugs. On the other hand, biosimilars, or copycat versions of biotech drugs, are harder and more expensive to develop as biotech drugs are made from living cells and cannot be identically replicated. Also, unlike generics, biosimilars are yet to take off in developed markets.
Hey, check out all the research scientist jobs. Post your resume today!
